The landscape of nanoparticle-based siRNA delivery and therapeutic development

Five small interfering RNA (siRNA)-based therapeutics have been approved by the Food and Drug Administration (FDA), namely patisiran, givosiran, lumasiran, inclisiran, and vutrisiran. Besides, siRNA delivery to the target site without toxicity is a big challenge for researchers, and naked-siRNA delivery possesses several challenges, including membrane impermeability, enzymatic degradation, mononuclear phagocyte system (MPS) entrapment, fast renal excretion, endosomal escape, and off-target effects. The siRNA therapeutics can silence any disease-specific gene, but their intracellular and extracellular barriers limit their clinical applications. For this purpose, several modifications have been employed to siRNA…

• BM
  Beijing Municipal Science and Technology Commission
• BN
  Beijing Nova Program

  Award: 20220484207
• NK
  National Key Research and Development Program of China

  Awards: 2021YFE0106900, 2021YFC2302400, 2021YFA1201000
• FR
  Fundamental Research Funds for the Central Universities

  Award: 2022CX01013